Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Biosciences to Review Strategic Alternatives

NEW YORK — Interpace Biosciences said on Thursday that it will undertake a strategic review of its business as it works to increase shareholder value following its recent delisting from the Nasdaq.

In February, Interpace announced that it had received a delisting notice from the Nasdaq for its failure to meet the exchange's minimum $2.5 million stockholders' equity requirement. At the time, the Parsippany, New Jersey-based company — which now trades on the Over-The-Counter Markets — also said that it was reorganizing in order to save $7.2 million in annual costs.

In April, Interpace reported that it was on track to meet this cost-cutting goal and that its revenues for the fourth quarter had more than doubled. On Thursday, the company said that it has raised its 2021 revenue guidance to between $42 million and $44 million from previous guidance of $38 million to $40 million.

Despite the expected revenue growth, Interpace said that its board believes its current stock price does not reflect the company's overall value. As a result, it is working with adviser Guggenheim Securities on a "review of a broad range of alternatives to enhance shareholder value."

During early morning trading, shares of Interpace were up $.60 to $8.50.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.